Zyversa therapeutics announces peer-reviewed publication demonstrating that inflammasome asc inhibitor ic 100 protects against stroke-related cardiovascular injury and dysfunction in preclinical trial

Stroke-related cardiovascular injury and dysfunction are induced by aim2 inflammasome activation in the heart, which can be blocked by zyversa's ic 100.
ASC Ratings Summary
ASC Quant Ranking